281 related articles for article (PubMed ID: 28436707)
1. SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.
Herold N; Rudd SG; Sanjiv K; Kutzner J; Bladh J; Paulin CBJ; Helleday T; Henter JI; Schaller T
Cell Cycle; 2017 Jun; 16(11):1029-1038. PubMed ID: 28436707
[TBL] [Abstract][Full Text] [Related]
2. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
[TBL] [Abstract][Full Text] [Related]
3. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
4. Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
Rassidakis GZ; Herold N; Myrberg IH; Tsesmetzis N; Rudd SG; Henter JI; Schaller T; Ng SB; Chng WJ; Yan B; Ng CH; Ravandi F; Andreeff M; Kantarjian HM; Medeiros LJ; Xagoraris I; Khoury JD
Blood Cancer J; 2018 Oct; 8(11):98. PubMed ID: 30341277
[TBL] [Abstract][Full Text] [Related]
5. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
Oellerich T; Schneider C; Thomas D; Knecht KM; Buzovetsky O; Kaderali L; Schliemann C; Bohnenberger H; Angenendt L; Hartmann W; Wardelmann E; Rothenburger T; Mohr S; Scheich S; Comoglio F; Wilke A; Ströbel P; Serve H; Michaelis M; Ferreirós N; Geisslinger G; Xiong Y; Keppler OT; Cinatl J
Nat Commun; 2019 Aug; 10(1):3475. PubMed ID: 31375673
[TBL] [Abstract][Full Text] [Related]
6. Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML.
Zhang F; Sun J; Tang X; Liang Y; Jiao Q; Yu B; Dai Z; Yuan X; Li J; Yan J; Zhang Z; Fan S; Wang M; Hu H; Zhang C; Lv XB
Cell Death Dis; 2022 Jul; 13(7):590. PubMed ID: 35803902
[TBL] [Abstract][Full Text] [Related]
7. Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.
Rudd SG; Tsesmetzis N; Sanjiv K; Paulin CB; Sandhow L; Kutzner J; Hed Myrberg I; Bunten SS; Axelsson H; Zhang SM; Rasti A; Mäkelä P; Coggins SA; Tao S; Suman S; Branca RM; Mermelekas G; Wiita E; Lee S; Walfridsson J; Schinazi RF; Kim B; Lehtiö J; Rassidakis GZ; Pokrovskaja Tamm K; Warpman-Berglund U; Heyman M; Grandér D; Lehmann S; Lundbäck T; Qian H; Henter JI; Schaller T; Helleday T; Herold N
EMBO Mol Med; 2020 Mar; 12(3):e10419. PubMed ID: 31950591
[TBL] [Abstract][Full Text] [Related]
8. SAMHD1 inhibits epithelial cell transformation in vitro and affects leukemia development in xenograft mice.
Kodigepalli KM; Li M; Bonifati S; Panfil AR; Green PL; Liu SL; Wu L
Cell Cycle; 2018; 17(23):2564-2576. PubMed ID: 30474474
[TBL] [Abstract][Full Text] [Related]
9. Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells.
Rothenburger T; Thomas D; Schreiber Y; Wratil PR; Pflantz T; Knecht K; Digianantonio K; Temple J; Schneider C; Baldauf HM; McLaughlin KM; Rothweiler F; Bilen B; Farmand S; Bojkova D; Costa R; Ferreirós N; Geisslinger G; Oellerich T; Xiong Y; Keppler OT; Wass MN; Michaelis M; Cinatl J
J Exp Clin Cancer Res; 2021 Oct; 40(1):317. PubMed ID: 34641952
[TBL] [Abstract][Full Text] [Related]
10. SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis.
Kodigepalli KM; Bonifati S; Tirumuru N; Wu L
Cell Cycle; 2018; 17(9):1124-1137. PubMed ID: 29911928
[TBL] [Abstract][Full Text] [Related]
11. The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1.
Knecht KM; Buzovetsky O; Schneider C; Thomas D; Srikanth V; Kaderali L; Tofoleanu F; Reiss K; Ferreirós N; Geisslinger G; Batista VS; Ji X; Cinatl J; Keppler OT; Xiong Y
Proc Natl Acad Sci U S A; 2018 Oct; 115(43):E10022-E10031. PubMed ID: 30305425
[TBL] [Abstract][Full Text] [Related]
12. With me or against me: Tumor suppressor and drug resistance activities of SAMHD1.
Herold N; Rudd SG; Sanjiv K; Kutzner J; Myrberg IH; Paulin CBJ; Olsen TK; Helleday T; Henter JI; Schaller T
Exp Hematol; 2017 Aug; 52():32-39. PubMed ID: 28502830
[TBL] [Abstract][Full Text] [Related]
13. SAMHD1 is a barrier to antimetabolite-based cancer therapies.
Rudd SG; Schaller T; Herold N
Mol Cell Oncol; 2017; 4(2):e1287554. PubMed ID: 28401188
[TBL] [Abstract][Full Text] [Related]
14. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
Morsy MHA; Lilienthal I; Lord M; Merrien M; Wasik AM; Sureda-Gómez M; Amador V; Johansson HJ; Lehtiö J; Garcia-Torre B; Martin-Subero JI; Tsesmetzis N; Tao S; Schinazi RF; Kim B; Sorteberg AL; Wickström M; Sheppard D; Rassidakis GZ; Taylor IA; Christensson B; Campo E; Herold N; Sander B
Blood; 2024 Jan; 143(19):1953-1964. PubMed ID: 38774451
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia.
Freisleben F; Behrmann L; Thaden V; Muschhammer J; Bokemeyer C; Fiedler W; Wellbrock J
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708452
[TBL] [Abstract][Full Text] [Related]
16. SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
Abdelrazak Morsy MH; Lilienthal I; Lord M; Merrien M; Wasik AM; Sureda-Gómez M; Amador V; Johansson HJ; Lehtiö J; Garcia-Torre B; Martin-Subero JI; Tsesmetzis N; Tao S; Schinazi RF; Kim B; Sorteberg AL; Wickström M; Sheppard D; Rassidakis GZ; Taylor IA; Christensson B; Campo E; Herold N; Sander B
Blood; 2024 May; 143(19):1953-1964. PubMed ID: 38237141
[TBL] [Abstract][Full Text] [Related]
17. SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia.
Marrero RJ; Cao X; Wu H; Elsayed AH; Klco JM; Ribeiro RC; Rubnitz JE; Ma X; Meshinchi S; Aplenc R; Kolb EA; Ries RE; Alonzo TA; Pounds SB; Lamba JK
Blood Adv; 2023 Jun; 7(11):2538-2550. PubMed ID: 36689724
[TBL] [Abstract][Full Text] [Related]
18. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine.
Rothenburger T; McLaughlin KM; Herold T; Schneider C; Oellerich T; Rothweiler F; Feber A; Fenton TR; Wass MN; Keppler OT; Michaelis M; Cinatl J
Commun Biol; 2020 Jun; 3(1):324. PubMed ID: 32581304
[TBL] [Abstract][Full Text] [Related]
19. Interference with SAMHD1 Restores Late Gene Expression of Modified Vaccinia Virus Ankara in Human Dendritic Cells and Abrogates Type I Interferon Expression.
Sliva K; Martin J; von Rhein C; Herrmann T; Weyrich A; Toda M; Schnierle BS
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462561
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]